CASE REPORT

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia

Ana R. Cid1, Pau Montesinos2, Isabel Sánchez-Guiu3, Saturnino Haya1, Jose I. Lorenzo2, Jaime Sanz2, Federico Moscardo2, Nieves Puig4, Dolores Panelles4, Santiago Bonanad1, Guillermo F. Sanz2, Vicente Vicente3, Consuelo González-Manchón5, María L. Lozano3, José Rivera3 & Miguel A. Sanz1,2

1Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
2Unidad de Trasplante de Células Hematopoyéticas, Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
3Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain
4Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain
5Departament Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (C.S.I.C.), Madrid, Spain

Correspondence
Ana R. Cid, Unidad Hemostasia y Trombosis, Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abril Martorell, 106, Valencia 46026, Spain. Tel: +34 961244297; Fax:+34 961246284; E-mail: cid_ana@gva.es

Funding Information
Research by the group of JR, MLA and VV is supported by grants from the Instituto de Salud Carlos III (PI14/01956 and CB15/00055) and the Fundación Seneca (19873/GERM/15).

Received: 28 January 2017; Revised: 27 July 2017; Accepted: 19 August 2017

Clinical Case Reports 2017; 5(11): 1887–1890
doi: 10.1002/ccr3.1206

Introduction

Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder characterized by either qualitative or quantitative abnormalities of integrin αIIbβ3 as a result of different mutations across genes ITGA2B and ITGB3 [1]. Recently, we characterized the largest series of GT in the Iberian Peninsula and identified novel causative mutations [2]. Patients often present recurrent and persistent mild mucocutaneous, or even life-threatening, bleeding, with hypermenorrhea being a major symptom in women. The clinical management of bleeding is generally based on local measures and antifibrinolytic agents for minor hemorrhages, and platelet concentrates (PCs) for major hemorrhages [3]. Some GT patients with a severe clinical history who develop antiplatelet antibodies (either anti-αIIbβ3 or against human leukocyte antigen [HLA]) become refractory to platelet transfusions [4]. In some of these patients, administration of recombinant factor VIIa (rFVIIa, NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark) could be successful [4, 5]. Allogeneic hematopoietic stem-cell transplantation is considered a curative treatment for this disease, but a balance must be struck between the morbidity–mortality of transplantation and its benefits. To date, several patients with GT have been successfully transplanted [6–16]. Remarkably, all these patients were children, except for one adult patient with GT who underwent HSCT due to a concomitant diagnosis of acute myeloblastic leukemia [11, 17]. We present the case of an adult GT female with antiplatelet antibodies and refractoriness to PCs, a poor responder to rFVIIa, who underwent HSCT from her HLA-identical...
male sibling. We describe the transplantation features and the long-term clinical outcome of this patient.

Case Report

Our female patient was diagnosed with GT at the age of 6. Her family did not present consanguinity, although the death of her sister aged 8 from bleeding after tonsillectomy is noteworthy. Clinically speaking, as an infant she presented unprovoked ecchymosis, epistaxis, gum bleeding, hemorrhages following tooth loss, and intestinal bleeding symptoms which required red blood cells and PCs transfusion. As of menarche, she presented heavy gynecological bleeding that did not respond to therapeutic measures. A complete hysterectomy was performed when she was 25 years old, which was complicated by excess bleeding that required the ligation of hypogastric arteries. Five months later, a bilateral ovarian hematoma required having to remove adnexal remains. Ever since then, her main clinical symptoms have included constant gum bleeding and epistaxis, treated with antifibrinolytics and nasal plugs, and occasionally a PCs transfusion. At the age of 44, excessive bleeding occurred after professional dental cleaning. Development of antiplatelet antibodies was investigated, and presence of anti-\(\text{ß}1\text{Ib/\(\text{ß}3\)}\) and anti-HLA was confirmed. Since then, her bleeding episodes have been treated with rFVIIa, but her response to this drug was poor. At the age of 47, she was admitted to hospital for persistent hematuria. A cystoscopy was performed, and a double J catheter was placed. However, controlling the hemorrhage proved difficult despite administration of rFVIIa and PCs. Given her poor quality of life with frequent hospitalizations because of bleeding (16 in 2 years), accompanied by the frequent usage of rFVIIa, she was evaluated for HSCT. Her GT diagnosis was re-evaluated and confirmed by additional platelet functional studies according to ISTH guidelines [18] (Figure 1). Molecular studies revealed that the patient was a compound heterozygote for two genetic variants in ITGB3 (c.448A/G [p.Met124Val] and c.774-775delTG [p.Cys258stop]) [2] (Figure 1). Thus, in February 2012, at the age of 50, a HSCT was performed from her HLA-identical brother. The donor was a heterozygous carrier of c.448A/G [p.Met124Val] (Figure 1), yet his platelet function analysis displayed no major platelet function abnormalities (not shown). At the baseline, the patient had a HSCT comorbidity index of 2 (depression and anxiety requiring consultation or treatment, and chronic C virus hepatitis with transaminases elevation up to 2 \times upper laboratory normal value). The source of hematopoietic progenitors was peripheral blood with partial T-lymphocyte depletion and positive CD34+ selection to prevent graft-versus-host disease (GvHD). Conditioning was performed with a myeloablative BUFLU regime, and GvHD prophylaxis included prednisone and cyclosporine. An immediate post-transplantation period took place with no relevant incidences, except for a mild urine infection. Platelet (>50 \times 10^9/L) and neutrophil (>0.5 \times 10^9/L) recovery occurred on day +10 and +18, respectively. She had no bleeding problems and platelets showed complete chimerism (97% donor). In spite of partial T-lymphocyte depletion and CD34+ selection, the patient developed severe chronic (c) GvHD (mild oral and conjunctival, cutaneous grade 2, hepatic 2, and intestinal grade 2), treated with several lines, including the sequential combination of prednisone, oral budesonide, mycophenolate, tacrolimus, thymoglobulin, and extracorporeal pheresis. As a result, the patient needed up to 22 hospitalizations in 4 years (mainly because of cGVHD and urinary tract infections), and very frequent outpatient visits at the day hospital. Although extensive cGVHD was stable, she was admitted to hospital in July 2016 with pneumonia and sepsis, which resulted in death in July 2016.

Discussion

The HSCT cases reported to date were carried out in children and young adults with GT and serious bleeding symptoms, both with and without antiplatelet antibodies, using bone marrow, umbilical cord, or peripheral blood stem cells [17]. Most of these patients had HLA-identical relatives, although a few have undergone non-family-related donor transplantation [10–12, 14, 15]. Adult patients tend to present higher morbidity and mortality after transplantation than children, including more severe GvHD. In spite of partial T-cell depletion, the patient developed severe cGVHD accompanied by frequent hospitalizations, use of medical resources, poor quality of life, and death by infectious complications. In view of the patient’s outcome, we should highlight that HSCT did improve neither the patient’s quality of life nor her life expectancy. The current experience reinforces that in future rare cases of adult patients with GT proposed for HSCT, this indication should be carefully assessed and may only be established when life-threatening hemorrhages take place. In addition, efficacious strategies to avoid GvHD should be recommended [19].

In summary, while research in the gene therapy area for GT is ongoing [3], HSCT is still the only currently available procedure to cure GT [3,20]. It is indicated in cases with recurrent life-threatening bleeding complications, particularly if patients are refractory to platelet transfusions. Transplantation should be performed preferably in childhood given the fewer risks of associated complications, mainly GvHD and platelet refractoriness. In adults, HSCT should be assessed on an individual basis and the risk of transplantation complications should be balanced against the risk of bleeding problems of GT and the ability to control bleeding with the available therapy.
Acknowledgments

The functional and molecular researches performed in this study were conducted according to the aims of Project “Functional and Molecular Characterization of Patients with Inherited Platelet Disorders” (approved by the Hemorrhagic Diathesis Working Group of the Spanish Society of Thrombosis and Hemostasis).

Authorship

ARC and PM: wrote the paper. PM, JIL, JS, FM, and GFS: planned transplantation and performed its monitoring. ISG, JR, MLL, and CGM: performed the platelet functional and molecular studies. All the authors critically reviewed and approved the final version of the paper.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Nurden, A. T., X. Pillois, M. Fiore, M.-C. Alessi, M. Bonduel, M. Dreyfus, et al. 2015. Expanding the mutation spectrum affecting αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum. Mutat. 36:548–561.
2. Sánchez-Guiu, I., A. I. Antón, J. Padilla, F. Velasco, J. F. Lucia, M. Lozano, et al. 2014. Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study. Orphanet J. Rare Dis. 9:357.

3. Solh, T., A. Botsford, and M. Solh. 2015. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J. Blood Med. 6: 219–227.

4. Poon, M.-C., R. D’Oiron, M. Von Depka, K. Khair, C. Negrier, A. Karafoulidou, et al. 2004. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J. Thromb. Haemost. 2:1096–1103.

5. Rajpurkar, M., M. Chitlur, M. Recht, and D. L. Cooper. 2014. Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia: a review of the literature. Haemophilia 20:464–471.

6. Bellucci, S., A. Devergie, E. Gluckman, G. Tobelem, P. Lethielleux, M. Benbunan, et al. 1985. Complete correction of Glanzmann’s thrombasthenia by allogeneic bone-marrow transplantation. Br. J. Haematol. 59:635–641.

7. Johnson, A., A. H. Goodall, C. J. Downie, A. Vellodi, and D. P. Michael. 1994. Bone marrow transplantation for Glanzmann’s thrombasthenia. Bone Marrow Transplant. 14:147–150.

8. McColl, M. D., and B. E. Gibson. 1997. Sibling allogeneic bone marrow transplantation in a patient with type I Glanzmann’s thrombasthenia. Br. J. Haematol. 99:58–60.

9. Bellucci, S., G. Damaj, B. Boval, V. Rocha, A. Devergie, I. Yacoub-Agha, et al. 2000. Bone marrow transplantation in severe Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 25:327–330.

10. Flood, V. H., F. L. Johnson, L. K. Boshkov, G. A. Thomas, D. J. Nugent, A. C. Bakke, et al. 2005. Sustained engraftment post bone marrow transplant despite antiplatelet antibodies in Glanzmann thrombasthenia. Pediatr. Blood Cancer 45:971–973.

11. Fujimoto, T.-T., M. Kishimoto, K. Ide, M. Mizushima, M. Mitn, N. Sezaki, et al. 2005. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int. J. Hematol. 81:77–80.

12. Connor, P., K. Khair, R. Liesner, P. Amrolia, P. Veys, P. Ancliff, et al. 2008. Stem cell transplantation for children with Glanzmann thrombasthenia. Br. J. Haematol. 140:568–571.

13. Ishaqi, M. K., M. El-Hayek, A. Gassas, M. Khanani, O. Trad, M. Baroudi, et al. 2009. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr. Blood Cancer 52:682–683.

14. Miller, W., A. Dunn, and K.-Y. Chiang. 2009. Sustained engraftment and resolution of bleeding phenotype after unrelated cord blood hematopoietic stem cell transplantation for severe Glanzmann thrombasthenia. J. Pediatr. Hematol. Oncol. 31:437–439.

15. Kitko, C. L., J. E. Levine, D. C. Matthews, and P. A. Carpenter. 2011. Successful unrelated donor cord blood transplantation for Glanzmann’s thrombasthenia. Pediatr. Transplant. 15:e42–e46.

16. Walz, A., A. Lenzen, B. Curtis, J. Canner, and J. Schneiderman. 2015. Use of allogeneic stem cell transplantation for moderate–severe Glanzmann thrombasthenia. Platelets 26:702–704.

17. Wiegering, V., K. Sauer, B. Winkler, M. Eyrich, and P. G. Schlegel. 2013. Indication for allogeneic stem cell transplantation in Glanzmann’s thrombasthenia. Hämostaseologie 33:305–312.

18. Gresele, P., for the Subcommittee on Platelet Physiology. 2015. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J. Thromb. Haemost. 13: 314–322.

19. Cheuk, D. K. 2013. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant. 3:99–112.

20. Poon, M.-C., G. Di Minno, R. d’Oiron, and R. Zotz. 2016. New insights into the treatment of Glanzmann thrombasthenia. Transfus. Med. Rev. 30:92–99.